中国糖尿病杂志
中國糖尿病雜誌
중국당뇨병잡지
CHINESE JOURNAL OF DIABETES
2006年
2期
146-147
,共2页
李红辉%覃国珍%丁殊节%唐平%何涛%李家富
李紅輝%覃國珍%丁殊節%唐平%何濤%李傢富
리홍휘%담국진%정수절%당평%하도%리가부
罗格列酮%组织型纤溶酶原激活物%纤溶酶原激活物抑制剂
囉格列酮%組織型纖溶酶原激活物%纖溶酶原激活物抑製劑
라격렬동%조직형섬용매원격활물%섬용매원격활물억제제
Plasminogen activator inhibitor
STZ诱导的糖尿病大鼠研究显示,罗格列酮治疗(每日4 mg/kg,3周)能增加组织型纤溶酶原激活物(tPA)的血浆水平,降低PAI-1的活性,降低PAI-1/tPA的比值.因此,罗格列酮可能有心血管保护作用.
STZ誘導的糖尿病大鼠研究顯示,囉格列酮治療(每日4 mg/kg,3週)能增加組織型纖溶酶原激活物(tPA)的血漿水平,降低PAI-1的活性,降低PAI-1/tPA的比值.因此,囉格列酮可能有心血管保護作用.
STZ유도적당뇨병대서연구현시,라격렬동치료(매일4 mg/kg,3주)능증가조직형섬용매원격활물(tPA)적혈장수평,강저PAI-1적활성,강저PAI-1/tPA적비치.인차,라격렬동가능유심혈관보호작용.
In the study of STZ-induced diabetic rats, rosiglitazone treatment (4 mg/kg·d, 3 weeks) inereased the plasma activity of tissue plasminogen activator (tPA) (P<0.05), and decreased the activity of PA inhibitor-1 (PAI-1) and ratio of PAI-1 to tPA (all P<0.01). Thus rosiglitazone enhances the activity of fibrinolytic system, which may play a role of cardiovascular protection.
